Choosing between prescription weight management treatments often involves reviewing medicines that work through different clinical pathways.
Wegovy and Orlistat are two treatments used in the UK under medical supervision for adults who meet specific eligibility criteria.
Although both medicines are prescribed to support weight management alongside lifestyle measures, they differ in how they are administered, how they affect the body, and how they are supplied through UK healthcare services.
The comparison below explains how the treatments differ across key factors, including mechanism of action, prescribing eligibility, consultation requirements, cost considerations, and monitoring.
Active ingredient and licensed use in the UK
Both medicines are approved for weight management in the UK, but they work through different biological mechanisms and are delivered in different ways.
Reviewing how each medicine functions helps explain why prescribing processes and monitoring requirements differ.
Wegovy and GLP-1 appetite regulation
Wegovy contains semaglutide, a GLP-1 receptor agonist that influences appetite regulation and feelings of fullness.
It is licensed by the MHRA for chronic weight management in adults with obesity or those who meet certain BMI thresholds alongside weight-related health conditions.
The medicine is delivered via Wegovy injections, administered once per week with a prefilled injection pen.
Treatment usually begins with a lower dose before gradually increasing to the maintenance dose as part of a supervised titration schedule.
Patients considering regulated access to weekly Wegovy weight loss injections usually complete a clinical assessment through a UK-registered prescribing service.
This process confirms whether the treatment can be supplied in accordance with approved prescribing guidance.
Orlistat and fat absorption
Orlistat works through a separate mechanism that acts within the digestive system. The medicine blocks lipase enzymes that normally break down dietary fat during digestion.
When these enzymes are inhibited, some fat consumed in meals is not absorbed by the body. Instead, it passes through the digestive system.
Because of this mechanism, Orlistat is taken orally as a capsule rather than via weight-loss injections.
Both treatments are licensed for weight management when used alongside dietary and lifestyle support, although their mechanisms and administration methods differ considerably.
Prescribing eligibility and UK criteria
Eligibility requirements for weight management medicines are defined by clinical guidance and regulatory frameworks in the UK.
While Wegovy and Orlistat share some similar thresholds, their access pathways can differ depending on where treatment is prescribed.
Eligibility for Wegovy
Wegovy is typically prescribed for adults with a BMI of 30 or above, or 27 or above with at least one weight-related medical condition, such as hypertension or type 2 diabetes.
Access through the NHS may involve referral to a specialist weight management service.
Private providers may also assess eligibility through clinician-led consultations that review BMI, medical history and any current medications before prescribing Wegovy injections.
Eligibility for Orlistat
Orlistat has similar eligibility thresholds but is generally more widely available through primary care.
The prescription-strength 120 mg version is commonly used for adults with a BMI of 30 or above, or 28 and above with associated health conditions.
A lower-dose 60 mg formulation can also be supplied by pharmacists after consultation.
This route allows individuals to access treatment through a pharmacy service following an assessment of BMI and overall suitability.
Consultation and prescription process
Weight management medicines are supplied through regulated prescribing systems in the UK.
The consultation process ensures that treatment is appropriate and that patients receive guidance on safe use.
Clinical assessment for Wegovy
Prescribing Wegovy usually involves a structured consultation with a clinician. During this review, the prescriber evaluates BMI, medical history, and current medications.
Patients who are prescribed Wegovy injections typically receive guidance on injection technique, dose-escalation schedules, and follow-up reviews.
Many regulated services offering weight-loss injections include ongoing monitoring to ensure the treatment remains appropriate throughout use.
Assessment process for Orlistat
The prescribing pathway for Orlistat is often simpler. A GP may prescribe the medicine after assessing BMI and suitability during a routine consultation.
Pharmacists can also supply the lower-dose OTC version after reviewing relevant health information.
The consultation usually includes a discussion of dietary habits, as the medicine works by reducing fat absorption during digestion.
Because the treatment is taken as a capsule with meals rather than as an injection, the prescribing process generally involves fewer steps than injectable therapies.
Cost structure and pricing transparency
The financial considerations associated with weight management treatments can vary depending on whether treatment is accessed through the NHS or privately.
Wegovy costs and access
Wegovy is available through limited NHS specialist services under NICE guidance. Access through these programmes depends on eligibility criteria and service availability.
Many patients who do not meet the strict NHS criteria explore private prescribing services.
In these settings, the cost of Wegovy injections is typically higher than that of oral weight management medicines due to the nature of the treatment and the monitoring involved.
Orlistat pricing and availability
Orlistat is widely available through both NHS prescriptions and pharmacy services. Patients receiving the medicine through the NHS pay the standard prescription charge unless exempt.
The lower-dose OTC formulation can be purchased directly from pharmacies after consultation.
Overall, the cost of Orlistat is often lower than that of injectable treatments, though pricing can vary by pharmacy or provider.
Side effect profile and monitoring requirements
Every prescription medicine has recognised side effects that clinicians review before treatment begins. Wegovy and Orlistat have different monitoring considerations because they act through separate mechanisms.
Monitoring Wegovy treatment
Wegovy is frequently associated with gastrointestinal symptoms during the early stages of treatment. Nausea, stomach discomfort and occasional vomiting can occur as the dose is gradually increased.
Clinicians often schedule follow-up reviews to monitor patients’ responses to Wegovy injections and confirm that dose escalation is tolerated.
Monitoring also helps ensure the treatment continues to align with the patient’s clinical profile.
Monitoring Orlistat use
Orlistat side effects are commonly related to dietary fat intake. Because the medicine blocks fat absorption, gastrointestinal symptoms may occur when meals contain higher fat content.
Clinical oversight typically focuses on ensuring the medicine remains appropriate and that patients understand the dietary considerations associated with treatment.
Monitoring requirements may therefore be less structured than those for weight loss injections, depending on the prescribing route.
Switching and long-term considerations
Patients sometimes review alternative treatment options if their circumstances change or if they wish to explore a different prescribing pathway.
Any change in weight management treatment should take place under clinical supervision.
Moving between treatments
A clinician reviewing a possible switch will usually assess BMI trends, medical history, previous treatment response, and any side effects.
If a patient moves from Orlistat to Wegovy injections, clinicians may discuss injection training, titration schedules and follow-up monitoring.
Moving in the opposite direction may involve reviewing dietary guidance and confirming that the oral treatment remains appropriate.
Ongoing support and treatment review
Weight management medicines are typically used alongside lifestyle support and periodic clinical review.
Ongoing discussions with a prescriber help determine whether treatment should continue, be adjusted, or be replaced with an alternative.
This process ensures that any weight-management medicine used remains aligned with the patient’s health profile and prescribing guidance.
Speak with a clinician before choosing a treatment
Wegovy and Orlistat differ in several practical ways. They use different mechanisms, follow different prescribing pathways and involve different monitoring approaches.
Wegovy is delivered via weight-loss injections, while Orlistat is taken orally with meals.
These differences mean the most appropriate option depends on a person’s BMI, health history, access to prescribing services and individual preferences regarding treatment type.
A clinician can review these factors and explain how each medicine fits within current prescribing guidance.
Feature image: Free to use from Unsplash
Join the discussion